U.S. Biosimulation Market Size & Outlook, 2021-2028
U.S. biosimulation market, 2016-2028 (US$M)
Related Markets
U.S. biosimulation market highlights
- The U.S. biosimulation market generated a revenue of USD 1,124.4 million in 2021 and is expected to reach USD 3,022.1 million by 2028.
- The U.S. market is expected to grow at a CAGR of 15.2% from 2022 to 2028.
- In terms of segment, software was the largest revenue generating product in 2021.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimulation market data book summary
| Market revenue in 2021 | USD 1,124.4 million |
| Market revenue in 2028 | USD 3,022.1 million |
| Growth rate | 15.2% (CAGR from 2021 to 2028) |
| Largest segment | Software |
| Fastest growing segment | Services |
| Historical data | 2016 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Software, Services |
| Key market players worldwide | Certara Inc Ordinary Shares, Dassault Systemes SE, Avantium NV, Simulations Plus Inc, Schrodinger Inc Ordinary Shares, Chemical Computing Group, Physiomics, Rosa & Co, Genedata AG, Instem, Yokogawa Electric Corp., Immunetrics |
Other key industry trends
- In terms of revenue, U.S. accounted for 46.3% of the global biosimulation market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In North America, U.S. biosimulation market is projected to lead the regional market in terms of revenue in 2028.
- Canada is the fastest growing regional market in North America and is projected to reach USD 304.0 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimulation Market Scope
Biosimulation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. biosimulation market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimulation market will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 69.14% in 2021. Horizon Databook has segmented the U.S. biosimulation market based on software, services covering the revenue growth of each sub-segment from 2016 to 2028.
The U.S. held a substantial share of North America biosimulation market in 2019 owing to high demand for cost-effective drug development by pharmaceutical companies. The uncertainty of clinical trials has compelled drug companies to introduce innovative methods to reduce costs and late-stage failure of clinical trials.
In 2012, the Obama administration in partnership with several federal agencies, including National Institutes of Health (NIH) and the National Science Foundation, created the Big Data Research and Development Initiative.
This initiative is aimed at improving the capability of government, researchers, and private industries in collecting, analyzing, and drawing inferences from the vast quantity of raw data gathered from various health records, national labs, and other sources.
Reasons to subscribe to U.S. biosimulation market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. biosimulation market databook
-
Our clientele includes a mix of biosimulation market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biosimulation market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biosimulation market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. biosimulation market size, by product, 2016-2028 (US$M)
U.S. Biosimulation Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
